Mast Cell Chemotaxis – Chemoattractants and Signaling Pathways by Ivana Halova et al.
REVIEW ARTICLE
published: 25 May 2012
doi: 10.3389/ﬁmmu.2012.00119
Mast cell chemotaxis – chemoattractants and signaling
pathways
Ivana Halova, Lubica Draberova and Petr Draber*
Department of Signal Transduction, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
Edited by:
Ulrich Blank, Université Paris-Diderot
Paris 7, France
Reviewed by:
Axel Lorentz, University of
Hohenheim, Germany
Jaroslaw Dastych, Institute of
Medical Biology of the Polish
Academy of Sciences, Poland
*Correspondence:
Petr Draber , Department of Signal
Transduction, Institute of Molecular
Genetics, Academy of Sciences of
the Czech Republic, Videnska 1083,
Prague 4 CZ142 20, Czech Republic.
e-mail: draberpe@img.cas.cz
Migration of mast cells is essential for their recruitment within target tissues where they
play an important role in innate and adaptive immune responses. These processes rely on
the ability of mast cells to recognize appropriate chemotactic stimuli and react to them
by a chemotactic response. Another level of intercellular communication is attained by
production of chemoattractants by activated mast cells, which results in accumulation of
mast cells and other hematopoietic cells at the sites of inﬂammation. Mast cells express
numerous surface receptors for various ligands with properties of potent chemoattrac-
tants. They include the stem cell factor (SCF) recognized by c-Kit, antigen, which binds to
immunoglobulin E (IgE) anchored to the high afﬁnity IgE receptor (FcεRI), highly cytokin-
ergic (HC) IgE recognized by FcεRI, lipid mediator sphingosine-1-phosphate (S1P), which
binds to G protein-coupled receptors (GPCRs). Other large groups of chemoattractants are
eicosanoids [prostaglandin E2 and D2, leukotriene (LT) B4, LTD4, and LTC4, and others]
and chemokines (CC, CXC, C, and CX3C), which also bind to various GPCRs. Further note-
worthy chemoattractants are isoforms of transforming growth factor (TGF) β1–3, which
are sensitively recognized by TGF-β serine/threonine type I and II β receptors, adenosine,
C1q, C3a, and C5a components of the complement, 5-hydroxytryptamine, neuroendocrine
peptide catestatin, tumor necrosis factor-α, and others. Here we discuss the major types
of chemoattractants recognized by mast cells, their target receptors, as well as signal-
ing pathways they utilize. We also brieﬂy deal with methods used for studies of mast cell
chemotaxis and with ways of how these studies proﬁted from the results obtained in other
cellular systems.
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INTRODUCTION
Mast cells are derived fromprogenitors that are released frombone
marrow into circulation, and subsequently migrate into periph-
eral tissues. Within this time period they undergo differentiation
and maturation. These processes are controlled by chemotactic
agents and growth factors present in circulation and at sites of
mast cell residency. In peripheral tissues the progenitors differ-
entiate into one of two possible classes of mature mast cells,
connective tissue, or mucosal mast cells. They differ in many
properties, including the mediators they produce and secrete.
Connective tissue mast cells are found in the skin, around blood
vessels, and in peritoneal cavity, whereas mucosal mast cells local-
ize in the linings of the lung and intestine. Differentiation of mast
cells into these two classes is directed by various growth factors
and chemoattractants produced by various cell types present in
the surrounding tissue environment. Accumulation of mast cells
within tissues is observed in many pathophysiological conditions.
Mature mast cells inﬁltrate the sites of inﬂammation associated
with chronic atopic disease or during helminthic or bacterial
infection. Directed migration of mature mast cells or their prog-
enitors might be one of the key mechanisms responsible for local
accumulation of these cells. This recruitment depends on the pres-
ence of chemical compounds named chemoattractants, which are
produced locally at sites of inﬂammation by various cell types.
Importantly,mast cells themselves can produce and secrete various
chemoattractants including adenosine, sphingosine-1-phosphate
(S1P), and leukotriene (LT) B4, and attract in this way other
mast cells and/or their progenitors by the autocrine/paracrine
fashion. Various chemoattractants and the corresponding recep-
tors are involved in mast cell migration and they can in part
share the downstream signaling pathways. Others use pathways
that are unique for each particular chemoattractant/receptor. This
divergence and convergence of signaling pathways is important
for proper cooperation among receptors triggered with various
chemoattractants, and contributes to speciﬁc behavior of mast
cells. There are two main types of migration, chemokinesis and
chemotaxis. Whereas chemokinesis is a random, non-vectorial
moiety, chemotaxis is directionalmigration towardhigher concen-
trations of a chemoattractant. This review deals with major types
of mast cell chemoattractants and their production, as well as with
signaling pathways they utilize. It starts with a brief description of
methods used for studies of mast cell chemotaxis.
METHODS USED FOR STUDIES OF MAST CELL CHEMOTAXIS
Numerous methods have been developed for studies on mast cell
migration, chemotaxis, and activity of various cytokines.Although
there are large numbers of mast cells in an adult organism, they
cannot be easily isolated because they are scattered throughout
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various parts of the body. In most of the studies, mast cells of
mouse, rat, and human origin have been used. In mice, bone mar-
row derived mast cells (BMMCs) are often studied. These cells can
be obtained by culturing bone marrow progenitors in the presence
of interleukin (IL)-3 and SCF (Razin et al., 1981; Tsai et al., 1991).
In rat,mast cells are often isolated in mature stage from peritoneal
cavity (Cooper and Stanworth, 1976; Poole and Zetter, 1983; Gru-
ber et al., 1994; Brzezin´ska-Błaszczyk et al., 2007). Human mast
cells are usually obtained by culturing mast cell progenitors from
various tissues in the presence of SCF, IL-6, and IL-10. Progeni-
tors from skin give rise to skin mast cells (SMCs; de Paulis et al.,
2001); those from intestine produce intestine mast cells (IMCs;
Fox et al., 1985; Feuser et al., 2012); progenitors from lungs, cord
blood,or peripheral blooddifferentiate, respectively into lungmast
cells (LMCs; Romagnani et al., 1999; Brightling et al., 2005b), cord
blood mast cells (CBMCs; Nilsson et al., 1994; Ochi et al., 1999;
Oskeritzian et al., 2008), or peripheral blood mast cells (PBMCs;
Saito et al., 2006;Aung et al., 2011).HumanBMMCshave been also
used in some studies (Brightling et al., 2005b). Chemotaxis was
also studied using mast cell lines, such as rat basophilic leukemia
(RBL) cells, clone 2H3 (Jolly et al., 2004, 2005; Toda et al., 2004),
humanmast cell line (HMC-1;Nilsson et al., 2000; Brightling et al.,
2005b; Lundeen et al., 2006; and others), or human lymphoma cell
line LAD-2 (Oskeritzian et al., 2008).
Experiments with various mast cell types have shown that
the expression pattern of surface receptors for chemoattractants
depends on origin of the cells and their maturation (Ochi et al.,
1999; Weller et al., 2005; Collington et al., 2010a). Results on the
effect of chemoattractants also depend on the method used. The
methods can be divided on methods in vivo and in vitro.
METHODS IN VIVO
Methods in vivo usually evaluate the accumulation of mast cells
at sites of chemoattractant injection. Chemoattractants are usu-
ally injected intradermally (i.d.) and mice are sacriﬁced at various
time intervals after injection. Skin at the site of injection is then
removed, ﬁxed, stained with toluidine blue, and examined by
microscopy to determine the number of mast cells (Matsui and
Nishikawa, 2005; Kitaura et al., 2005b).
Alternatively,mast cell progenitors or mature mast cells are iso-
lated and cultured up to deﬁnite developmental stages. The cells
are then labeled with various trackers (ﬂuorescent or radioactive)
followed by intravenous (i.v.) tail vein injection some time before
i.d. injection of chemoattractant into dorsal skin. The mice are
then sacriﬁced and skin biopsies are evaluated depending on the
tracker used (Weller et al., 2005, 2007; Boehme et al., 2009;Colling-
ton et al., 2010a). In such experiments, mast cells obtained from
mice deﬁcient in speciﬁc genes could be injected into mice deﬁ-
cient in mast cells to determine the role of selected molecules in
chemotaxis. Exposure of the cells to antibodies speciﬁc for selected
surface receptors can be used for determination of the possible role
of the receptors in mast cell chemotaxis (Brightling et al., 2005b;
Kitaura et al., 2005b; Kuehn et al., 2010).
METHODS IN VITRO
Most of the assays on chemotaxis in vitro utilized various
modiﬁcations of Boyden’s chamber where cells migrate toward
chemoattractants through pores (usually 5 or 8 μm) of polycar-
bonate membrane. Common is the use of Transwell permeable
supports placed into 24-well polystyrene plates. Mast cells are
introduced into theupper chamber,which is placed into awell con-
taining chemotaxis buffer supplementedwith the chemoattractant
at selected concentration. The plates are kept for several hours
(usually 2–8) at 37˚C in CO2 incubator. The cells migrate toward
chemoattractant through the pores of the membrane and accu-
mulate at the bottom of the well. The number of cells is counted
with a hemocytometer or ﬂow cytometer. Alternatively, the cells
are labeled with ﬂuorescent dye and quantiﬁed by determining the
ﬂorescence (Weller et al., 2005; Kuehn et al., 2010; Tu˙mová et al.,
2010).
In some experiments the membranes were modiﬁed by coat-
ing with different substances, such as laminin or ﬁbronectin, or
epithelial cells (Nilsson et al., 1994; Oliveira and Lukacs, 2001;
Kitaura et al., 2005b) and migration was evaluated by counting
the number of migrated cells. Boyden chamber-based assays can
also be used for identiﬁcation of molecules or signaling pathways
involved in chemotaxis. One major advantage of this system is its
simplicity and ability to test many compounds at different concen-
trations simultaneously, to examine the role of pharmacological
inhibitors on chemotaxis, and also to analyze chemokinesis, which
reﬂects migration independent on the presence of chemoattrac-
tants. However, this method has its limitation. One of them is
that only sharp chemotactic gradient can be generated and it is
impossible to assess the speed of migration of individual cells or
directions of movement of the cells.
Methods analyzing individual migrating cells in real time are
often based on microscopic technique and on recording the cell
movement in selected time intervals. These real time methods
could be combined with different modiﬁcations of under-agarose
or “tunnel” assays, which are used for studying multiple chemo-
tactic gradients, shape and speed of migrating cells, or assessing
the roles of selected adhesion molecules (Poole and Zetter, 1983;
Heit et al., 2002). In the under-agarose method, tissue culture
dishes are precoated with a blocking agent such as BSA, calf
serum, or collagen, and then overlaid by agarose. After agarose
solidiﬁes, three holes of 3mm in diameter and 3mm apart are
punched in the gel. Mast cells are dispensed to the middle hole and
chemoattractants to the others. The migration is observed under
microscope in real time or the migrated cells can be stained at the
end of the assay and quantiﬁed. This method can also be mod-
iﬁed by using speciﬁc inhibitors, activators, or antibodies (Heit
et al., 2002). The obtained images can by analyzed by cell tracking
plugins: http://rsb.info.nih.gov/ij/; http://www.imagescience.org/
meijering/software/mtrackj; or http://www.ibidi.com/applications
/ap_chemo.html
Horizontal chemotactic assays in KK chambers (Kanegasaki
et al., 2003) were used for studying the migration of BMMCs
toward antigen. KK chambers consist of etched silicon substrate
and a ﬂat glass plate that forms compartment with a 5-μm-deep
microchannel. A charge-coupled device camera is used to record
the migrating cells (Kanegasaki et al., 2003; Sawada et al., 2005).
The main advantage of recording the cells in real time is that
investigators can observe not only individual migrating cells but
also their dynamic behavior during the process. This method
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in combination with cells carrying ﬂuorescently tagged proteins
could also be useful for studying the involvement of these proteins
in chemotaxis.
MAST CELL CHEMOATTRACTANTS
Numerous chemoattractants have been described capable of
inducing chemotaxis in mast cells. Some of them, and corre-
sponding receptors, are summarized in Table 1 and described
below.
STEM CELL FACTOR
Stem cell factor, also known as steel factor or c-Kit-ligand, is a
hematopoietic growth factor that promotes survival, proliferation,
and differentiation of hematopoietic cells (for review see Roskoski,
2005; Okayama and Kawakami, 2006; Jensen et al., 2008). It is pro-
duced in both soluble and membrane-bound form by alternative
splicing of the same RNA transcript, and is a major chemotactic
factor for mast cells and their progenitors (Chabot et al., 1988;
Meininger et al., 1992; Nilsson et al., 1994, 1998). SCF is produced
by awide variety of cells including ﬁbroblasts and endothelial cells.
Its receptor, c-Kit, is a type III tyrosine kinase broadly expressed on
mature mast cells and eosinophils. SCF promotes recruitment of
mast cell progenitors into tissues, as well as their local maturation
and activation. It also promotes eosinophil survival, maturation,
and functional activation (Chabot et al., 1988; Okayama and
Kawakami, 2006). Binding of SCF to the cell induces dimerization
of the receptors, followed by their transphosphorylation at tyro-
sine residues (Tyr568 and Tyr570) and consequently formation
of docking sites for the Src-homology (SH) 2-containing signal
transduction molecules. It has been demonstrated that Src-family
protein tyrosine kinases Lyn and Fyn are phosphorylated and acti-
vated after c-Kit triggering (Linnekin et al., 1997; Timokhina et al.,
1998) and that the event leads to further propagation of the signal
(Figure 1).
There are several signaling pathways resulting in degranula-
tion, survival, and migration of mast cells. An important path-
way depends on PI3K and subsequent phosphorylation of Akt,
and is therefore related to c-Kit-dependent mast cell survival.
Fyn-dependent axis leads to the phosphorylation of Gab2, medi-
ates through small GTPase Rac the cytoskeleton reorganization
and inﬂuences mast cell migration (Linnekin et al., 1997; Tim-
okhina et al., 1998; Samayawardhena et al., 2006; Samayaward-
hena et al., 2007). Studies with different murine c-Kit mutants
showed the importance of Y719 and Y567 for c-Kit-mediated
chemotaxis. Phosphorylated Y719 recruited PI3K and mediated
thus an enhanced Ca2+signal, which was found to be critical for
chemotaxis. In contrast,phosphorylatedY567 recruitedLynor Fyn
resulting in activation of p38 pathway, also important for chemo-
taxis (Ueda et al., 2002; Samayawardhena et al., 2006). Decreased
migration toward SCF was observed in cells with a defect in
expression of protein tyrosine phosphatase (PTPα; Samayaward-
hena and Pallen, 2008). When compared to wild-type cells, the
PTPα-deﬁcient cells exhibited reduced Fyn kinase activity caus-
ing defects in phosphorylation of tyrosines 567/569 and 719
of c-Kit. PI3K and Akt activation was unaffected in PTPα−/−
BMMCs. Thus PTPα is required for SCF-induced migration
which employs the Fyn/Gab2/Shp2/Vav/PAK/Rac/JNK signaling
axis (Samayawardhena and Pallen, 2008). Chemotaxis is also pos-
itively regulated by Fes kinase because migration of Fes−/− mast
cells toward SCF was decreased (Smith et al., 2010).
Studies with macrophages showed regulation of PI3K-
dependent migration by negative feedback of phosphatase and
tensin homolog (PTEN; Papakonstanti et al., 2007). Knock-down
of PTEN in mast cells led to increased basal level of PIP3 and con-
stitutive activation of Akt, p38, and JNK, resulting in enhanced
survival and increased production of several cytokines, including
IL-3, IL-6, and tumor necrosis factor (TNF)-α in antigen-activated
cells (Furumoto et al., 2006). It was also shown that PTEN deﬁ-
ciency enhanced the number of mast cells in different tissues.
This suggested that PTEN could play a regulatory role in mast cell
chemotaxis (Furumoto et al., 2006). Experiments with neutrophils
showed that SHIP1, other phosphatase regulating amount of PIP3,
was even more important for migration than PTEN (Nishio et al.,
2007; Subramanian et al., 2007). Interestingly, SHIP1 knock-out
mice exhibited mast cell hyperplasia in several tissues (Haddon
et al., 2009),which could be also consequence of increased chemo-
taxis. Elucidation of the role of these two phosphatases in mast cell
chemotaxis requires further studies.
Mammalian target of rapamycin complexes (mTORCs) were
found to play important roles in chemotaxis of several cell mod-
els such as neutrophils (Charest et al., 2010; Liu et al., 2010) and
Dictyostelium (Sasaki and Firtel, 2006; Takeda et al., 2007; Liu
and Parent, 2011). mTORC1 is activated in PI3K-dependent man-
ner and its inhibition by rapamycin depressed the SCF-mediated
migration (Kim et al., 2008a,b). mTORC2 appears to play an
important role inPGE2-mediated chemotaxis (Kuehn et al., 2011b;
see below) but its role in SCF- or antigen-mediated chemotaxis is
to be deﬁned.
In this connection, it should be mentioned that patients with
c-Kit mutation D816V exhibit constitutive activation of c-Kit
and accumulation of mast cells derived from CD34+CD117+
mast cell precursors. Experiments with such precursors obtained
from patients with mastocytosis showed that only less than 10%
prechemotactic sample had D816V mutation, whereas as many
as 40–80% of migrated cells showed the mutation (Taylor et al.,
2001). The results indicate that D816V mutation in c-Kit enhances
the SCF-dependent chemotaxis and could promote in this way the
mastocytosis.
ANTIGEN
FcεRI is a tetrameric receptor consisting of an immunoglobulin
E (IgE)-binding α chain, β chain, and two γ chains. Binding of
IgE to α chain and subsequent crosslinking of the receptor by the
multivalent antigen leads to phosphorylation of immunorecep-
tor tyrosine-based activation motifs (ITAMs) in the cytoplasmic
tails of the FcεRI β and γ chains by Lyn kinase (Figure 2; Eise-
man and Bolen, 1992; Yamashita et al., 1994). Phosphorylated
ITAMs are able to bind a broad variety of positive as well as nega-
tive regulators of immunoreceptor signaling. The most important
propagator of the positive signal is a protein tyrosine kinase Syk,
which after binding to phosphorylated tyrosines of ITAM assumes
an active conformation facilitating its phosphorylation by Lyn and
further increase in enzymatic activity. Consequently, Syk phos-
phorylates a number of its downstream targets critical for further
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Table 1 | Summary table of different mast cell chemoattractants and their receptors.
Chemoattractant* Receptor Mast cell model (organism used) Reference
SCF c-KIT (CD117) BMMCs (mouse), PMCs (mouse),
CBMCs (human), HMC-1 (cell line,
human)
Meininger et al. (1992), Nilsson et al. (1994),
Samayawardhena et al. (2006)
Antigen, HC IgE FCεRI MC-9 mast cell clone (mouse),
BMMCs (mouse)
Ishizuka et al. (2001), Kitaura et al. (2005b),
Tu˙mová et al. (2010)
S1P S1PR1, S1PR2 BMMCs (mouse), LAD-2 (cell line,
human), CBMCs (human), RBL-2H3
(cell line, rat)
Olivera et al. (2006), Oskeritzian et al. (2008),
Jolly et al. (2004, 2005)
PGE2 EP3 BMMCs (mouse) Weller et al. (2007), Kuehn et al. (2011b)
PGD2 DP1, DP2 (CRTh2) BMMCs (mouse) Lewis et al. (1982), Boehme et al. (2009)
LTB4 BLT1, BLT2 BMMCs (mouse), HMC-1 (cell line,
human), CBMCs (human)
Lundeen et al. (2006), Weller et al. (2005)
LTD4, LTC4 CysLT1R, CysLT2R CD34+ hematopoietic progenitors
(human)
Bautz et al. (2001)
CCL3 (MIP-1α), CCL5 (RANTES), CCL7
(MCP-3), CCL14 (HCC-1), CCL15
(MIP-1δ), CCL16 (HCC-4), CCL23 (MPIF-1)
CCR1 LMCs (human), BMMCs (human),
CBMCs (human), RBL-2H3 (cell line,
rat)
Brightling et al. (2005b), Juremalm et al.
(2002), Scott and Bradding (2005), Toda et al.
(2004)
CCL 5 (RANTES), CCL7 (MCP-3), CCL8
(MCP-2), CCL11 (eotaxin), CCL13
(MCP-4), CCL15 (MIP-1δ), CCL24
(eotaxin-2), CCL26 (eotaxin-3), CCL28
(MEC)
CCR3 LMCs (human), BMMCs (human),
CBMCs (progenitors, human), SMC
(human)
Brightling et al. (2005b), Ochi et al. (1999),
Romagnani et al. (1999), Romagnani (2002), de
Paulis et al. (2001), Scott and Bradding (2005)
CCL5 (RANTES) CCR4 LMCs (human), CBMCs (human) Brightling et al. (2005b), Juremalm et al. (2002)
CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5
(RANTES), CCL11 (eotaxin)
CCR5 CBMCs (progenitors, human) Ochi et al. (1999), Scott and Bradding (2005)
CCL16 (HCC-4), CCL20 CCR6 IMCs (human) Feuser et al. (2012)
CCL19 (MIP-3β), CCL21 (6Ckine) CCR7 LMCs (human), BMMCs (human)
IMCs (human)
Brightling et al. (2005b), Feuser et al. (2012)
CCL1 CCR8 IMCs (human) Feuser et al. (2012)
CXCL6 (GCP-2), CXCL8 (IL-8) CXCR1 LMCs (human), BMMCs (human),
CBMCs (human) IMCs (human)
Brightling et al. (2005b), Inamura et al. (2002),
Feuser et al. (2012)
CXCL8 (IL-8) CXCR2 CBMCs (human) IMCs (human) Inamura et al. (2002), Ochi et al. (1999), Feuser
et al. (2012)
CXCL9 (Mig), CXCL10 (IP-10), CXCL11
(I-TAC)
CXCR3 CBMCs (progenitors and mature,
human), synovial MCs (human),
LMCs (human), HMC-1 (cell line,
human), IMCs (human)
Ochi et al. (1999), Ruschpler et al. (2003),
Brightling et al. (2005a), Feuser et al. (2012)
CXCL12 (SDF-1α) CXCR4 LMCs (human), BMMCs (human),
HMC-1 (cell line, human), CBMCs
(progenitors, human), IMCs
(human), BMMC (mouse
Brightling et al. (2005b), Ochi et al. (1999),
Feuser et al. (2012), Byrne et al. (2008)
CXCL16 (GCP-2) CXCR6 LMCs (human), BMMCs (human),
IMCs (human)
Scott and Bradding (2005), Brightling et al.
(2005b), Feuser et al. (2012)
(Continued)
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Table 1 | Continued
Chemoattractant* Receptor Mast cell model (organism used) Reference
CX3CL1 (fractalkine) CX3CR1 BMMCs (mouse), IMCs (human) Papadopoulos et al. (2000), Feuser et al. (2012)
TGF-β TGF-β I and II
receptors
CMC3 (cell line, mouse), PMCs
(rat), HMC-1 (cell line, human),
CBMCs (human), MCs (mouse)
Gruber et al. (1994), Olsson et al. (2000),
Matsui and Nishikawa (2005)
Adenosine Adenosine
receptors
BMMCs (mouse) Kuehn et al. (2010)
C1q cC1q-R, gC1q-R C57 (cell line, mouse), HMC-1 (cell
line, human)
Ghebrehiwet et al. (1995)
C3a C3AR1 HMC-1 (cell line, human), CBMCs
(human), SMCs (human)
Hartmann et al. (1997), Nilsson et al. (1996)
C5a C5AR HMC-1 (cell line, human), CBMCs
(human), SMCs (human)
Hartmann et al. (1997), Nilsson et al. (1996)
PAF PAF-receptor HMC-1 (cell line, human), BMMCs
(mouse), CBMCs (human)
Nilsson et al. (2000)
5-hydroxytryptamine 5-HT receptors BMMCs (mouse), PBMCs (human) Kushnir-Sukhov et al. (2006)
Catestatin ** LAD-2 (cell line, human), PBMCs
(human)
Aung et al. (2011)
TNF-α TNF-α receptor PMC (rats) Brzezin´ska-Błaszczyk et al. (2007),
Misiak-Tloczek and Brzezin´ska-Blaszczyk
(2009)
Glycyl-histidyl-lysine,
N -formyl-methionyl-leucyl-phenylalanine
(tumor derived peptides)
** PMC (rats) Poole and Zetter (1983)
Adrenomedullin ** HMC-1 Zudaire et al. (2006)
*For chemokines both new and old (in parenthesis) names are used in accord to chemokine nomenclature (Zlotnik andYoshie, 2000).
**Speciﬁc receptors for the chemoattractants in mast cells have not yet been identiﬁed.
PMCs, peritoneal mast cells; RANTES, regulated upon activation, normal T-cell expressed and secreted.
propagation of the signal. These targets include transmembrane
adaptor proteins, linker of activated T cells (LAT), and non-T cell
activation linker (NTAL), as well as cytosolic adaptor proteins,
such as growth factor receptor-bound protein 2 (Grb2), Grb2-
associated binder (Gab2), Grb2-related adaptor downstream of
Shc (Gads), SH2 domain containing leukocyte protein of 76 kDa
(SLP-76) and others that often function in cooperation with var-
ious signaling proteins, forming multicomponent signaling units,
signalosomes. Phosphorylated LAT associates directly or indirectly
with numerous signalingmolecules such asGrb2,phospholipaseC
γ1 (PLCγ1), guanine nucleotide exchange factor Vav, Cbl, SLP-76,
and Gads (Gilliland et al., 1992; Buday et al., 1994; Sieh et al.,
1994; Trub et al., 1997; Finco et al., 1998; Zhang et al., 1998;
Liu et al., 1999; Ishiai et al., 2000). Phosphorylated NTAL inter-
acts with a similar set of proteins except for PLCγ1; this is an
important difference explaining in part different roles of these
two adaptors in mast cell signaling (Brdicˇka et al., 2002; Janssen
et al., 2003; Volná et al., 2004; Zhu et al., 2004; Draber et al.,
2012). Further propagation of the signal activates PI3K, PLCγ,
protein kinase C (PKC), and mitogen-activated protein kinase
(MAPK).
Whereas the signaling pathways leading to degranulation and
production of cytokines are relatively well understood, those
involved in mast cell migration and chemotaxis are still vague.
The ﬁrst report on molecules involved in antigen-induced mast
cell migration showed that p38 MAPK, MAPK-activated protein
kinase 2 (MAPKAPK2) and Rho-associated kinase (ROCK) are
involved (Ishizuka et al., 2001). Studieswith BMMCs isolated from
NTAL−/−mice showed an important role of NTAL in antigen-
induced migration. Absence of NTAL resulted in enhanced migra-
tion toward antigen, when compared to cells from wild-type mice;
this negative regulatory role of NTAL is probably mediated by
small GTPase RhoA and its kinase ROCK (Tu˙mová et al., 2010).
RhoA regulates cortical ﬁlamentous (F)-actin disassembly, which
is dependent on enhanced levels of free cytoplasmic calcium (Sulli-
van et al., 1999). Immunoreceptor activation leads to Ca2+ release
from intracellular stores, which is followed by entry of external
Ca2+ into the cells through store operated Ca2+ (SOC) channels.
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FIGURE 1 | SCF-mediated chemotaxis. Crosslinking of the plasma
membrane (PM) anchored c-Kit by SCF results in dimerization of the receptor
and its auto-transphosphorylation. This is followed by recruitment of
SH2-domain containing proteins such as PI3K and Grb2 to c-Kit. Activated
PI3K generates PIP3, a binding site for PH-domain containing protein Btk, and
facilitates further propagation of the signal through activation of PLCγ. An
increased activity of PLCγ leads to production of DAG and IP3 and release of
Ca2+. This is followed by actin rearrangements and chemotactic response.
Production of PIP3 also leads to recruitment of phosphoinositide-dependent
kinase (PDK)-1 and Akt to the plasma membrane and subsequent
phosphorylation of Akt by PDK1. Akt directly phosphorylates the negative
regulator of mTORC1, inactivating thereby its inhibitory action. PIP3 levels are
negatively regulated by phosphatases PTEN and SHIP1. Grb2 orchestrates
activation of Ras by recruiting Ras and Rho family GEFs, Sos, and Vav.
Through Ras, both p38 and Erk are activated and chemotaxis is also promoted
in this way. Signaling molecules in bodies are those located at their sites of
action and/or bound to the indicated target molecules; other signaling
molecules are presented as plain text.
SOC inﬂux depends on the presence of aggregated stromal inter-
action molecule 1 (STIM1; Dráber and Dráberová, 2005; Liou
et al., 2005; Roos et al., 2005). The importance of SOC inﬂux in
immunoreceptor-directed chemotaxis was recently documented
in studies with BMMCs deﬁcient in STIM1. The defect resulted in
inhibitionof antigen-inducedCa2+ response,decreased formation
of microtubule protrusions and impaired chemotactic response to
antigen (Hájková et al., 2011). Experiments with pharmacological
inhibitors showed that both Src and Syk kinases are important
for antigen-mediated chemotaxis, whereas Tec kinases are not.
These results were conﬁrmed in studies using BMMCs derived
from mice deﬁcient in Syk, Btk, Lyn, Fyn, and Hck. Furthermore,
the results demonstrated that Lyn is more important than Fyn,
and that Hck has no fundamental role in this process. Studies with
other inhibitors showed that PI3K, MAP kinases, p38, JNK, and
PKC are all essential for antigen-mediated chemotaxis, unlike PKA
or Rho-kinase (Kitaura et al., 2005b). The results with Rho-kinase
and JNK are, however, in conﬂict with those presented by Ishizuka
et al. (2001).
PI3K appears in several isoforms, and PI3Kδ is the major reg-
ulator of chemotactic responses to antigen (Kuehn et al., 2010).
In the cited study, the authors also showed the importance of
Btk for antigen-mediated migration, which seems to disagree with
other published data. Kitaura et al. (2005b) reported that antigen-
mediated chemotaxis operates in an autocrine–paracrine manner
by releasing other chemoattractants such as monocyte chemoat-
tractant protein (MCP)-1, LTB4, and adenosine, promoting
chemotaxis toward antigen, and that Tec kinases are not involved
in this process. These discrepancies could be attributable to dif-
ferent methods used for evaluation of chemotaxis: ﬁbronectin-
coated polycarbonate membranes (Kitaura et al., 2005b), against
uncoated membranes (Kuehn et al., 2010). It is known that
ﬁbronectin binds integrin and that the mechanisms of integrin-
mediated migration differ from those of integrin-independent
movement (Narumiya and Watanabe, 2009; Renkawitz et al.,
2009).
It has been reported that pretreatment of mast cells with SCF
leads to inhibition of chemotaxis toward antigen (Sawada et al.,
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FIGURE 2 | Antigen-mediated chemotaxis. Aggregation of the FcεRI by
multivalent antigen leads to rapid Lyn kinase-mediated phosphorylation of
tyrosine residues in ITAM motifs of FcεRI β and γ subunits. This is followed
by anchoring of Syk to FcεRI γ through interaction of Syk SH2 domains with
phosphorylated ITAMs. Syk then phosphorylates transmembrane adaptor
proteins NTAL and LAT and creates binding sites for various SH2-containing
proteins like Grb2. In this way it brings PI3K and Gab2 to the plasma
membrane. Activated PI3K generates PIP3, a binding site for PH-domain
containing protein Btk. This leads to further propagation of the signal
through activation of PLCγ, resulting in Ca2+ release and actin
rearrangement. Levels of free intracellular Ca2+ are positively regulated by
aggregated STIM1. Another PI3K-dependent pathway contributes to
activation of p38 and consequently to enhanced chemotactic response.
Grb2 orchestrates activation of Ras by recruiting small GTPases Ras and
Rho family GEFs, Sos, Vav, and other signaling molecules, resulting in actin
rearrangement and chemotaxis. NTAL could play a negative regulatory role
in chemotaxis through activation of Rho/ROCK pathway that is responsible
for controlling the rear edge of the migrating cell. ROCK could also activate
the PTEN phosphatase which inhibits activity of PI3K and in this way
decreases the PIP3 levels.
2005). The authors suggested that in vivo locally produced SCF
may have inhibitory effects on chemotaxis in mast cells with acti-
vated FcεRI. This could foster the accumulation of mast cells at
sites of inﬂammatory reactions. In contrast, chemotactic response
of cells exposed simultaneously to antigen and SCF was higher
than the response toward antigen alone, but lower than that
induced by SCF alone (Tu˙mová et al., 2010). However, different
results were obtained in other experiments in which antigen and
SCF added together caused a considerably higher chemotactic
response than any of them alone (Kuehn et al., 2010). These
discrepancies probably reﬂect differences in cells used, employed
assays of migration, and/or other variables.
Antigen-mediated engagement of FcεRI also has a distinct
capacity to potentiate the action of PGE2, adenosine, and probably
other chemoattractants (Zhong et al., 2003; Kuehn and Gilﬁllan,
2007; Kuehn et al., 2008, 2010). The observed crosstalk between
signaling pathways that are induced by different activators might
play an important role in mast cell physiology.
HIGHLY CYTOKINERGIC IgE
Mast cell activation and migration can also be induced by HC IgE
in the absence of antigen (Kitaura et al., 2005a,b). The pathways
andmolecules involved in this process appear to be similar to those
implicated in processes where IgE FcεRI complexes are aggregated
by multivalent antigen.
SPHINGOSINE-1-PHOSPHATE
The lipid mediator S1P takes part in diverse biological processes,
from vascular, and neural development to regulation of lym-
phocyte trafﬁcking (Olivera, 2008; Rivera et al., 2008). S1P is
produced by intracellular phosphorylation of sphingosine by two
phylogenetically conserved sphingosine kinases SphK1 and SphK2
(Olivera and Spiegel, 2001). However, S1P can also be produced
extracellularly by the secreted form of SphK1 (Ancellin et al.,
2002). Intracellular levels of S1P are tightly regulated by a balance
between its synthesis and degradation, occurring either reversibly
by two speciﬁc S1P phosphatases or irreversibly by S1P lyase. It has
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been suggested that S1P lyase and S1P phosphatases can also inﬂu-
ence the concentrations of S1P in the interstitium of lymph nodes
and spleen, and probably other tissues as well, allowing the cells in
those microenvironments to respond to local changes in S1P con-
centration (Schwab et al., 2005; Peest et al., 2008).Although SphK1
and SphK2 are highly homologous, they are not fully redundant
functionally. SphK1 plays a positive role in cell growth and survival
(Olivera et al., 1999), whereas overexpression of SphK2 induces
cell death (Liu et al., 2003). On the other hand, studies employ-
ing geneticallymanipulatedmice showed that knock-outs of either
SphK1or SphK2 separatelywere viable,had only slightly decreased
S1P levels and exhibited no obvious phenotypes, whereas double
SphK1/SphK2 knock-outs resulted in a complete loss of S1P and
were embryonically lethal. It implies that these kinases have some
redundant and overlapping functions (Mizugishi et al., 2005).
Activation of FcεRI inmast cells correlatedwith increased activ-
ity of both SphKs, enhanced the formation of intracellular S1P,
and promoted the export of S1P into extracellular space by spe-
ciﬁc ATP-binding cassette (ABC)-type transporters. After secre-
tion, S1P can act in an autocrine/paracrine-dependent manner.
Although both SphK1 and SphK2 have been implicated in regula-
tion of S1P production in mast cells, the details are still obscure.
Loss of SphK2 in murine mast cells reduced S1P production and
caused a substantial inhibition of FcεRI-mediated degranulation
as well as diminished production of IL-6, IL-13, and TNF-α,
primarily due to reductions in intracellular calcium levels and
PKC activation. In contrast, SphK1-deﬁciency lowered the level
of circulatory S1P in vivo and altered mast cell functions (Olivera
et al., 2007). SphK1 unlike SphK2 is critical in human mast cells
for antigen-induced degranulation, chemoattractants secretion,
and migration, while both isozymes are important for cytokine
secretion (Oskeritzian et al., 2008). It should be noted that down-
regulation of SphK1 alsomitigated the rapid and transient increase
in intracellular calcium induced by FcεRI crosslinking (Melendez
and Khaw, 2002). SphKs phosphorylation, probably by Erk, as
well as their recruitment to the proximity of cell membrane close
to their substrates, are necessary steps for their complete activa-
tion (Figure 3). Two Src-family kinases, Lyn and Fyn, play crucial
roles in early stages of FcεRI activation and are irreplaceable in
activations of SphKs. Lyn was found important for the early onset
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FIGURE 3 | Production of S1P after FcεRI triggering and S1P-mediated
chemotaxis. FcεRI triggering leads to rapid activation of Lyn and Fyn kinases
and Lyn-mediated phosphorylation of tyrosine residues of ITAM motifs in
FcεRI β and γ subunits. This is followed by anchoring of Syk to FcεRI and
enhanced enzymatic activity of Syk. Lyn kinase interacts directly with SphK1
and recruits it to the proximity of FcεRI, whereas Fyn kinase mediates the
recruiting of Gab2 and PI3K to the membrane and foster in this way the
activation of SphK1. Phosphorylation of sphingosine (SPH) by SphK1 leads to
S1P formation. Sphingosine is an inhibitor of SOC channels. Formation of S1P
results therefore in the release of SOC channels block. S1P can be
transported from cytoplasm to the extracellular space by ABC-type
transporter. Extracellular S1P then serves as a potent chemoattractant and
promotes inﬂammation by recruiting other immune cells. Alternatively, S1P
can affect mast cell activation and/or chemotaxis via two independent GPCRs,
the S1PR1 and the S1PR2. S1PR1 acts via Gi subunit and induces mast cell
migration by inhibiting of adenylate cyclase (AC) and activation of small
GTPases Rac and Cdc42. S1PR2 is coupled to G12/13 subunits that activate
adenylate cyclase and thereby inhibit chemotaxis.
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of SphK1 activity by interacting directly with SphK1; this interac-
tion facilitates the recruitment of this lipid kinase to FcεRI (Urtz
et al., 2004). In contrast, Fyn was found obligatory for activation
of both SphKs. Fyn phosphorylates Gab2, which then binds the
p85 regulatory subunit of PI3K (Parravicini et al., 2002). Both
Gab2 and PI3K activities were essential for SphK1 activation, and
were partially responsible for SphK2 activation. This indicates that
additional Fyn-dependent, PI3K-independent signals are required
for activation of SphK2 (Olivera et al., 2006).
As already mentioned, S1P can mediate mast cell functions
through its intracellular and extracellular activities. The intracel-
lular targets of S1P have not yet been fully identiﬁed, but a direct
correlation was found out between S1P production and uptake
of Ca2+. Sphingosine and its structural analogs act as speciﬁc
inhibitors of SOC inﬂux. Thus, one possible mechanism where
by SphK2 might exert its activating effect on calcium inﬂux could
be mediated through reduction of the level of sphingosine by its
phosphorylation, derepressing in this way the blocking of the SOC
channels (Mathes et al., 1998). S1P released from the cells can func-
tion as a ligand for a family of ﬁveG-protein-coupled S1P receptors
(S1PR) 1–5. Evident diversity in the expression pattern of S1PRs
can be seen in cells of the immune system. S1PR1 is expressed
by most immune cells, whereas other receptors (S1PR2–5) have
a more limited distribution. All ﬁve receptors were found to be
expressed in dendritic cells, whereas mast cells and macrophages
express only S1PR1 and S1PR2; eosinophiles express S1PR1–3,
T cells S1PR1 and S1PR4, B-cells S1PR1 and S1PR3, and NK
cells S1PR5 (Rivera et al., 2008). S1PRs expressed on mast cells
can react with S1P by paracrine/autocrine mechanism. S1P levels
in tissues increase under inﬂammatory conditions. Extracellular
S1P has chemotactic activity and can attract mast cells to sites
of inﬂammation. Furthermore, S1P produced by mast cells can
induce their degranulation and cytokine production. S1PRs, like
other GPCRs, transduce signals by associating with G-proteins.
S1PR1 interacts with Gi, which can modulate different pathways
leading to cell survival through the PI3K/Akt pathway, cell migra-
tion through the PI3K and Rac pathways, and cell proliferation
through the Erk pathway. In contrast, S1PR2 is coupled to Gi, Gq,
and G12/13; the latter two are responsible for degranulation. Exper-
iments with knock-out or knock-down of S1PR1 and/or S1PR2
indicated that these receptors have a non-overlapping function
in mast cells. Loss of S1PR1 resulted in decreased chemotactic
motility, whereas loss of S1PR2 inhibited mast cell degranulation.
Because of the fact that concentrations of S1P required for degran-
ulationwere higher than those required for chemotaxis (Jolly et al.,
2004) and higher concentrations of S1P also inhibited chemotaxis
(Jolly et al., 2005), it has been suggested that mast cells in allergic
inﬂammatory reactions would migrate to target tissues at low S1P
concentration gradients. However, after reaching the target, higher
S1P concentrations would prevent further migration and the cells
could start to degranulate in response to a more extensive ligation
of S1PRs (Olivera and Rivera, 2005).
EICOSANOIDS
Upon activation with speciﬁc antigen, complement or other
transmembrane stimuli, mast cells produce several eicosanoids
through activation of cytoplasmic phospholipase A2 (cPLA2),
which releases free arachidonic acid from the plasma mem-
brane (Figure 4). Free arachidonic acid can be metabolized
to eicosanoids by three distinct pathways. One depends on
the activity of lipoxygenases (LOXs) and leads to production
of leukotrienes such as LTB4, LTC4, and LTD4. The second is
dependent on cyclooxygenases (COXs), which are engaged in
the mechanisms responsible for production of prostaglandins
such as PGE2 and PGD2. The third includes the cytochrome
P450 monooxygenase that metabolizes arachidonic acid into
epoxyeicosatrienoic acids (EETs), hydroxyeicosatetraenoic acids
(HETEs), andhydroperoxyeicosatetraenoic acids (HPETEs;Boyce,
2007; Wang and Dubois, 2010).
As indicated above, the key enzyme in initial stages of these
processes is cPLA2. It can be activated by two major routes.
One is Erk dependent and results in phosphorylation of the
enzyme (Berenbaum et al., 2003), and the other appears to be
Erk independent but rides on PI3K/Btk/PLCγ pathway enabling
Ca2+-dependent translocation of cPLA2 to the membrane (Clark
et al., 1991; Kramer and Sharp, 1995, 1997).
Eicosanoids can act as proinﬂammatory mediators through
speciﬁc receptors and serve as chemoattractants for various cell
types including mast cells and their progenitors. The balance
between self-secreted mediators and those produced by other cells
is responsible for the paracrine versus autocrine regulation of mast
cells (Boyce,2007).More informationon thesemediators and their
effects on mast cells is given below.
Prostaglandin E2
Eicosanoid PGE2 is synthesized and secreted in response to inﬂam-
matory stimuli bymany cell types, includingdendritic cells, epithe-
lial cells, ﬁbroblasts, macrophages, and mast cells. Physiological
functions of PGE2 are mediated by four types of GPCRs, EP1–4.
Each of these receptors is unique in tissue distribution, pharma-
cology, and action mechanism. The EP1 receptor is coupled to
PLC and its stimulation leads to the increase in intracellular Ca2+.
Engagement of EP2 and EP4, induces an increase in cAMP level via
G-proteinα-subunit stimulationof adenylate cyclase. EP3 receptor
exists in several isoforms generated by alternative splicing; these
isoforms are coupled with different G-proteins (Gi, Gq, and Gs).
The major signaling pathways described for EP3 receptor lead to a
decrease in intracellular cAMP levels and increase in intracellular
Ca2+(Ichikawa et al., 1996; Kuehn and Gilﬁllan, 2007). In FcεRI-
triggered cells, PGE2 regulates activation in positive or negative
way, depending on the EP receptors engaged (Figure 5). Enhance-
ment of FcεRI-mediated degranulation and cytokine production
was described for mouse BMMCs activated by PGE2 bound to
EP3 receptor (Gomi et al., 2000; Nataraj et al., 2001; Nguyen et al.,
2000) or for human mast cells with PGE2 bound to EP1 or EP3
(Wang and Lau, 2006). Another study reported inhibition of his-
tamine, eicosanoids, and TNF-α production in human mast cells
triggered by binding of PGE2 to EP2 receptor, followed by inhi-
bition of elevated cAMP levels (Kay et al., 2006). Recently, PGE2
was described to act as a chemotactic factor for immature as well
as mature murine mast cells in vitro (Weller et al., 2007). The
same study described accumulation of mast cells in vivo after i.d.
injection of PGE2 (Weller et al., 2007). It was also shown that
PGE2 mediated chemotactic response in human mast cells (Kuehn
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FIGURE 4 | Synthesis of eicosanoids and their actions in mast cells.
Synthesis of eicosanoids is initiated by activation of cPLA2 via Erk-dependent
pathway, followed by Ca2+-dependent translocation of cPLA2 to the plasma
membrane where it liberates the arachidonic acid. Free arachidonic acid can
be metabolized by three independent pathways: lipoxygenase pathway,
cyclooxygenase pathway and cytochrome P450 monooxygenase pathway.
The 5-lipoxygenase in cooperation with FLAP mediates transition of
arachidonic acid to unstable LTA4. LTA4 is subsequently converted to LTB4,
LTC4, and LTD4. In the cyclooxygenase pathway, arachidonic acid is converted
to intermediate PGH2 by peroxidase activity of COX enzymes. PGH2 is then
metabolized by speciﬁc enzymes to ﬁnal products that include PGE2 and
PGD2. Cytochrome P450 metabolizes arachidonic acid to epoxyeicosatrienoic
acids (EETs), hydroperoxyeicosatetraenoic acids (HPETEs), and
hydroxyeicosatetraenoic acids (HETEs). The ﬁnal products are transported
outside the cell by speciﬁc multidrug resistance protein (MRP) ABC-type
transporters and can act there as chemoattractants for mast cells, their
progenitors or other cells. Eicosanoids mediate their action via different
GPCRs (BLT1, BLT2, CysLT1, CysLT2, EP2, EP3, DP1, and DP2) localized on
the plasma membrane of target cells. Eicosanoids in red bodies are those
secreted from mast cells and acting as chemoattractants on various targets.
et al., 2011a). Biochemical studies showed that PGE2 mediated
chemotaxis in mast cells through engagement of GPCRs linked
to EP3 receptor. Unlike the FcεRI or c-Kit, GPCRs do not require
the engagement and activation of tyrosine kinases and protein
tyrosine phosphorylation for initial propagation of the signals
but reckon instead on coupling to a heterotrimetric complex of
Gα and Gβγ subunits (Dorsam and Gutkind, 2007). PGE2 acti-
vation of the EP3 receptor initiated mobilization of PI3K and
Akt, but this pathway in contrast to antigen-mediated triggering,
was independent of Btk. Other targets involved in PGE2-induced
chemotaxis, downstream of PI3K, are still vaguely understood.
Two forms of mTOR, the mTORC1 and mTORC2, have recently
been found to be activated downstream of PI3K in BMMCs
and have therefore been suspected to play an important role in
PGE2-mediated chemotaxis. However, pharmacological studies
with speciﬁc inhibitors of mTORCs as well as siRNA knock-down
experiments showed that only mTORC2 cascade was selectively
utilized in chemotaxis towardPGE2. EP3-induced chemotaxis thus
differs from c-Kit-mediated chemotaxis,which is partly controlled
also by mTORC1 (Kim et al., 2008a). Rac-dependent actin reor-
ganization has also been observed in PGE2-mediated chemotaxis
but it makes use of a different pathway independent of mTORC2
(Kuehn et al., 2011b).
Prostaglandin D2
Eicosanoid PGD2 is another arachidonic acid metabolite with
important roles in various inﬂammatory diseases. It is produced
by IgE-activated mast cells through the COX pathway (Lewis et al.,
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FIGURE 5 | PGE2-mediated chemotaxis. PGE2 mediates its
chemotactic action on mast cells via Gi-coupled EP3 receptor. After
activation the α-subunit of G-protein inhibits adenylate cyclase (AC) and
thereby causes a decrease of cAMP which leads to stimulation of
migration. This stimulation also results in activation of mTORC2, an
important regulator of actin rearrangements and positive regulator of
chemotaxis. mTORC2 can also inﬂuence PKC-dependent activation of
small GTPase Rho and subsequent activation of PTEN through ROCK.
This can act as a negative feedback for production of PIP3 by PI3K that
is also activated by PGE2 in mast cells.
1982). PGD2 was found to bind to two different prostaglandin
receptors, Gs-coupled DP1 that stimulates adenylate cyclase, and
DP2 (also known as chemoattractant receptor-homologous mol-
ecule expressed on Th2 cells, CRTH2) that is coupled to Gi. These
two membrane-bound receptors show extensively antagonistic
effects. PDG2 was found to inhibit migration of several cell types
such as dendritic cells andLangerhans cells through theDP1 recep-
tor (Hammad et al., 2003; Angeli et al., 2004; Yamamoto et al.,
2011), and to stimulate migration of lymphocytes, eosinophils,
and basophils via the DP2 receptor (Hirai et al., 2001; Shiraishi
et al., 2005; Yamamoto et al., 2011). The DP2-dependent migra-
tion has recently been reported also for mast cells (Boehme et al.,
2009).
Leukotriene B4
Eicosanoid LTB4, as a potent activator and chemoattractant for
leukocytes, is implicated in various inﬂammatory diseases. It is
produced from arachidonic acid via the 5-LOX pathway by innate
immune cells such as neutrophils, macrophages, and mast cells
(Toda et al., 2002; Osher et al., 2006; Ohnishi et al., 2008). The
action of LTB4 is mediated by two GPCRs, the BLT1 and BLT2.
BLT1, a high afﬁnity receptor for LTB4, is expressed predominantly
in leukocytes including granulocytes, monocytes, macrophages,
dendritic cells, effector T cells, and mast cells (Yokomizo et al.,
1997; Yokomizo et al., 2000), whereas BLT2, a low afﬁnity recep-
tor which can also bind to some other eicosanoids is expressed
ubiquitously (Yokomizo et al., 2000). Both BLT1 and BLT2 cou-
ple to the inhibitory Gi protein, inhibit adenylate cyclase, activate
PLCγ to increase intracellular Ca2+, and induce robust chemo-
taxis (Yokomizo, 2011). Mouse BLT2 is highly expressed in small
intestine and skin, and BLT2-selective agonist induces chemo-
taxis in primary mouse keratinocytes and BMMCs. Triggering
of BMMCs by LTB4 induces transient Erk and Akt phosphoryla-
tion without any changes of p38 phosphorylation (Lundeen et al.,
2006).
LTB4 serves as a potent chemoattractant for mast cell prog-
enitors, but not mature mast cells (Weller et al., 2005). It was
also shown that BLT2 is upregulated in cells activated via FcεRI.
Knock-down of BLT2 resulted in reduced NOX1-Ros-mediated
production of Th2 cytokines such as IL-4 and IL-13 (Cho et al.,
2010). On the other hand, exposure of BMMCs to SCF, another
chemoattractant and activator, resulted indownregulationof BLT1
and BLT2 expression and inhibition of migration toward LTB4
(Lundeen et al., 2006).
Leukotriene D4 and Leukotriene C4
Similarly to LTB4, the LTD4, and LTC4 are produced in activated
mast cells via the LOX pathway (Razin et al., 1983). These two
leukotrienes act through two speciﬁc receptorsCysLT1 andCysLT2
that have non-redundant functions in mast cells and are cou-
pled to distinct intracellular signaling pathways. CysLT1 receptor
is bound to Gq proteins, whereas CysLT2 receptor uses Gi/Go pro-
teins for calcium-independent signaling (Bautz et al., 2001; Möhle
et al., 2001; Mellor et al., 2003). Both LTD4 and LTC4 were found
to function as co-mitogens for low concentrations of SCF (Jiang
et al., 2006, 2007). LTD4 induces migration and transendothelial
migration of CD34+mast cell progenitors (Bautz et al., 2001).
CHEMOKINES
Chemokines are members of a superfamily of 8–15 kDa heparin-
binding chemotactic cytokines that function as potent chemoat-
tractants for different cell types in the immune system.
Although they are not homologous sequentially, they share a
similar three-dimensional structure. There are four subclasses of
chemokines classiﬁed according to the location of the ﬁrst two cys-
teines in their sequence: CC, CXC, C, and CX3C (where X stands
for any amino acid). Major families, the CC and CXC, have more
than 50 members, whereas C and CX3C families are much smaller
with only one or a few members per family. Some chemokines are
expressed constitutively by many cell types in tissue-speciﬁc man-
ner. Expression of other chemokinesis induced only under speciﬁc
conditions, typically in response to inﬂammatory signals (Kaplan,
2001; Sabroe et al., 2002; Juremalm and Nilsson, 2005; Scott and
Bradding, 2005; Lloyd and Brown, 2006; Hallgren and Gurish,
2011). Chemokine receptors belong to GPCRs, and are mostly
capable of binding more than one chemokine. Considerable dif-
ferences in the expression of chemokine receptors exist between
mature and immature mast cells and among individual mast cell
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subtypes. For example,mast cells derived fromprogenitors present
in human cord blood express several chemokine receptors includ-
ing CCR3 (eotaxin receptor), CCR5 [receptor for the Th1-active
chemokinemacrophage inﬂammatory protein (MIP)-1α],CXCR2
(IL-8 receptor), and CXCR4 [receptor for the constitutively pro-
duced lymphocyte chemoattractant stromal cell-derived factor
(SDF)-1α]. Only the CCR3 was retained on mature human mast
cells (Ochi et al., 1999; Bautz et al., 2001).
Chemokines exhibit a different pattern of expression depend-
ing on mast cell type. For example, CCR3, CXCR1, CXCR3, and
CXCR4 were found to be highly expressed by human LMCs,
and their respective ligands, i.e., CCL11 (eotaxin), CXCL8 (IL-
8), CXCL10, interferon γ-induced protein (IP)-10, and CXCL12
(SDF-1α), mediated LMC chemotaxis (Brightling et al., 2005a,b).
Interestingly, the CXCR3 was missing among those reported to
be expressed on human BMMCs. Cord blood-derived mast cells
and LMCs from patients with allergic asthma expressed CCR1 and
CCR4 (Juremalm et al., 2000, 2002; Amin et al., 2005) and CCR3
was expressed in human skin and intestinal mast cells (Romagnani
et al., 1999). Recent work testing the expression of chemokines
and chemokine receptors showed that human intestinal mast
cells expressed nine chemokine receptors (CCR6–8, CXCR1–4,
XCR1, and CX3CR1) and 27 chemokines. Whereas expression
of chemokine receptors was independent of antigen stimulation,
the expression of 12 chemokines (CCL1–CCL5, CCL7, CCL18,
CCL20, CXCL2, CXCL3, CXCL8, and XCL1) was more than
fourfold upregulated upon antigen triggering (Feuser et al., 2012).
Mouse mast cells also express several chemokine receptors.
Studies with mouse BMMCs showed expression of mRNA for
CCR1–5 and its upregulation after activation through c-kit or
FcεRI (Oliveira and Lukacs, 2001). Chemotaxis assays showed that
mast cells migrated toward CCL2 and CCL5. If IgE-sensitized cells
were exposed to antigen, enhanced migration was also observed
toward CXCL4 and CCL3 (Taub et al., 1995). In another study
mouse BMMCs expressed CCR3 mRNA, but the corresponding
protein was not detected and migration toward CCR3 ligands
(CCL11 and CCL24) was noticed neither in mature nor imma-
ture cells. In addition, no phenotypic differences between WT and
CCR3−/− mice were found (Collington et al., 2010b, 2011). The
observed differences could be attributed to different mouse strains
chosen or different methods used for growth of the cells. The
ﬁrst group (Oliveira and Lukacs, 2001) cultured BMMCs in the
presence of IL-3 and SCF (both at a concentration of 15 ng/ml),
whereas in the second study only IL-3 at 5 ng/ml was used. The
data also suggest that the role of CCR3 in chemotaxis depends not
only on cell origin (mouse versus human) but also onphysiological
settings. Expression of different chemokines could be responsible
for mast cell homing into different tissue. Impaired homing was
found in mouse mast cell progenitors lacking genes for selected
chemokine receptors. When CXCR2−/− cells were used, mast cells
were absent in intestine but still present in lung, spleen, or bone
marrow (Abonia et al., 2005). Homing to intestines was unaltered
in mice lacking CCR2, CCR3, and CCR5. On the other hand,
knock-out of CCR3 led to an increased number of intratracheal
mast cells (Humbles et al., 2002; Hallgren and Gurish, 2007;
Hallgren et al., 2007). Immature BMMCs, when cultured in the
presence of IL-3 and SCF but not IL-3 alone,migrated in response
to CCL2. Recruitment of mast cell progenitors to the allergen-
sensitized lungs was signiﬁcantly reduced in both CCR2−/− and
CCL2−/− mice. However, repopulation studies using sublethally
irradiated and bone marrow reconstituted mice indicated that
receptor and ligand expression was more important on stromal
cells than mast cells (Collington et al., 2010a). Dermal mast cells
were found to play a critical role in the induction of immune sup-
pression. UV exposure caused increased migration of mast cells
from skin to the draining lymph nodes. This was mediated by
interaction of CXCR4 expressed on mast cells with CXCL12 that
is up regulated in lymph node B-cells (Byrne et al., 2008).
Murine BMMCs of both connective tissue and mucosal phe-
notype were also found to express CX3CR1 and were attracted by
its chemoattractant CX3CL1 (fractalkine), which is a membrane-
bound peptide. Fractalkine was unable to induce degranulation
quantiﬁed by the release of granule-associated β-hexosaminidase
(Papadopoulos et al., 2000).
TRANSFORMING GROWTH FACTOR β
Multifunctional transforming growth factor (TGF)-β is a pep-
tide that plays a key role in tissue cell growth, differentiation,
morphogenesis, and formation of extracellular matrix, as well
as in coordination of the complex events leading to tissue repair
after injury. Its pivotal function within the immune system is to
maintain tolerance by regulating the lymphocyte proliferation,
differentiation, and survival. Furthermore, TGF-β controls the
initiation and resolution of inﬂammatory responses through the
regulation of chemotaxis and activation of lymphocytes, dendritic
cells, natural killer cells, granulocytes, and mast cells. Through
its pleiotropic effect on various immune cells, TGF-β prevents
the development of autoimmune diseases without compromising
the efﬁciency of immune responses toward pathogens (Wrzesin-
ski et al., 2007). Initial studies on chemotaxis showed that TGF-β
at femtomolar concentrations caused directed migration of cul-
turedmouse cells,withmaximal chemotactic response observed at
25 fM. In its ability to induce directed migration, TGF-β was sub-
stantially more efﬁcient on the molar basis than other mast cell
chemoattractants, including SCF (Gruber et al., 1994). Detailed
studies showed that TGF-β3, one of the three isoforms of TGF-
β, was more effective than TGF-β1 and TGF-β2 when tested at a
constant concentration of 40 fM. The effect was observed in both
human mast cell line HMC-1 and cultured primary mast cells.
Furthermore, TGF-β1, TGF-β2, and less efﬁciently TGF-β3 inhib-
ited the proliferation of HMC-1 cells. The migratory responses
were probablymediated through interaction of all TGF-β isoforms
with TGF-β serine/threonine type I and II receptors that were
found expressed in HMC-1 cells (Olsson et al., 2000). Application
of peptidoglycan from Staphylococcus aureus to barrier-disrupted
abdominal skin lead to accumulation of mast cells at the site
of application. This accumulation was abrogated by administra-
tion of TGF-β1 Ab. These results suggest that peptidoglycan have
ability to induce mast cell accumulation through TGF-β1 produc-
tion by epidermal keratinocytes (Matsui and Nishikawa, 2005).
All combined, the data indicate that TGF-β isoforms are highly
potent chemoattractants for mast cells and could possibly play
an important role in the recruitment of mast cells to the sites of
inﬂammatory reactions.
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ADENOSINE
The purine nucleoside adenosine is produced by numerous cell
types in response to cell stress and hypoxia. It binds to four types
of adenosine receptors, A1, A2A, A2B, and A3. The latter three were
found expressed on mast cells (Ramkumar et al., 1993; Ralevic and
Burnstock, 1998). These receptors are GPCRs and are coupled to
different G-proteins: A2A receptor to Gs, A2B to Gs or Gq and A3
to Gi or Gq (Kuehn and Gilﬁllan, 2007). Adenosine regulates mast
cell activities positively or negatively, depending on the plasma
membrane receptor involved and mast cell type (Kuehn and Gil-
ﬁllan,2007;Brown et al., 2008). It has been reported that adenosine
regulates FcεRI-mediated mast cell degranulation, cytokine pro-
duction, and chemotaxis. Binding of adenosine to A2A receptor
also blocked the potassium channel, KCa3.1, and inhibited migra-
tion of human LMCs in response to asthmatic airway smooth
muscle conditioned medium (Duffy et al., 2007). Adenosine alone
was unable to cause migration of BMMCs but it potentiated the
migration toward antigen in a pertussis-toxin dependent manner.
This points to A3 receptor coupled to Gi (Kuehn et al., 2010). It
may possible be relevant that purine and pyrimidine nucleotides
ADP,ATP, and UTP, acting at low micromolar concentrations, also
caused directed migration of rat BMMCs (McCloskey et al., 1999).
Other chemoattractants
There are several other molecules that are recognized by mast cells
as chemoattractants. Human C1q is a collagen-like glycoprotein
that associates with the Ca2+-dependent Clr2Cls2 tetramer, form-
ing the ﬁrst component of complement, C1. C1q induces mast cell
migration in a speciﬁc and dose-dependent manner. Two speciﬁc
receptors were found on murine and human mast cells, the cC1q-
R that binds to the collagen-like stalk of Clq, and the gC1q-R that
binds to the globular “heads” of C1q (Ghebrehiwet et al., 1995).
C3a and C5a are other complement components which are
potent chemoattractants for eosinophils and neutrophils but in
addition can attract mast cells and basophils. The chemotactic
response is blocked by pertussis-toxin, suggesting that Gi-coupled
receptors are involved in signal transduction (Nilsson et al., 1996;
Hartmann et al., 1997).
Platelet-activating factor (PAF) is a potent phospholipid
inﬂammatory mediator that is released from a variety of cells,
including endothelial cells, neutrophils, and macrophages. PAF
acts via binding to a speciﬁc GPCR. PAF was also found to induce
mast cellmigration in pertussis-toxin dependentmanner this indi-
cates that Gi-coupled receptor is involved in this process (Nilsson
et al., 2000).
Another chemoattractant, the 5-hydroxytryptamine (5-HT), is
implicated in enhancing inﬂammatory reactions of skin, lung, and
gastrointestinal tract. It was reported that both human and mouse
mast cells expressed a variety of 5-HT GPCRs, but the predom-
inant receptor mediating the effects like adhesion and migration
on these cells was the 5-HT1A Gi-coupled receptor. Mast cells
also synthesize 5-HT, which can function in both paracrine and
autocrine manner (Kushnir-Sukhov et al., 2006).
Recently published studies also showed that the neuroen-
docrine peptide catestatin, as well as its naturally occurring vari-
ants were capable of inducing migration, degranulation, and
production of cytokines, eicosanoids, and chemokines, in both
human mast cell line LAD-2 and peripheral blood-derived mast
cells (Aung et al., 2011).
Furthermore, proinﬂammatory cytokines were capable of
inducing chemotaxis.Mast cellswere shown tomigrate in response
to IL-6 or TNF-α stimulation. IL-6-stimulated mast cell migration
was the result of chemokinesis, whereas TNF-α-induced migra-
tion was based on chemotaxis (Brzezin´ska-Błaszczyk et al., 2007;
Misiak-Tloczek and Brzezin´ska-Blaszczyk, 2009). In contrast, IL-
10 inhibited mast cell migration toward RANTES, TNF-α, and
nerve growth factor (Pietrzak et al., 2011).
Mast cells were also found to accumulate in proximity of var-
ious malignant tumors. It has been shown that tumor-derived
tripeptides glycylhistidyllysine and N -formyl-methionyl-leucyl-
phenylalanine are potent chemoattractants for rat peritoneal
mast cells, suggesting that they could be important in early
events of tumor neovascularization (Poole and Zetter, 1983).
Adrenomedullin is another peptide amid produced by human can-
cer cells that was found to be chemotactic for HMC-1 (Zudaire
et al., 2006).
LESSONS FROM OTHER CELLS
There exist two important cellularmodels for studying chemotaxis
of eukaryotic cells, neutrophils, and Dictyostelium. Both can detect
very shallow differences in the surrounding gradients of chemoat-
tractants and are thereby capable of quickly changing directions of
their movement. Because GPCRs that have often been the subjects
of studied on chemotaxis of the two cell types are also involved in
migration of mast cells, the knowledge obtained in studies on neu-
trophils and Dictyostelium can be helpful for better understanding
of chemotaxis in mast cells. In migrating cells, two sides can be
distinguished, the front side (also called leading edge) and the rear
side. Concentration of chemoattractants reaching the cell surface
is, consequently highest in the front and lowest in the rear. In both,
neutrophils and Dictyostelium, one of the ﬁrst processes occurring
in the leading edge after sensing chemoattractant is activation of
PI3K resulting in accumulation of PIP3 in the leading edge mem-
brane (Nilsson et al., 1996; Hartmann et al., 1997; Funamoto et al.,
2001, 2002; Huang et al., 2003). PIP3 than serves as a binding
site for a diversity of pleckstrin homology (PH)-domain contain-
ing proteins. The most important proteins recruited appear to
be guanine nucleotide exchange factors (GEFs) for Rac GTPases,
such as dedicators of cytokinesis (DOCKs). Their recruitment
leads to activation of small GTPase Rac and subsequently local-
ized polymerization of F-actin. The rear side of neutrophils is
engaged in activation of another small GTPase RhoA that activates
ROCK and makes thus possible the phosphorylation of myosin
light chain. These signals are mediated by different G-proteins.
At the leading edge, it is mediated by a Gi-coupled protein which
inhibits adenylate cyclase, whereas G12/13 promote back signal by
myosin II. Despite the fact that generating PIP3 is crucial for cell
migration, inhibition of PIP3 formation in neutrophils (Ferguson
et al., 2007; Heit et al., 2008), or in Dictyostelium (Loovers et al.,
2006; Andrew and Insall, 2007) did not, at least under certain
circumstances, fully inhibited cell migration, but only slowed it
down. The data suggest that PIP3 accumulation is not essential for
direction of chemotaxis but controls the extent of random genera-
tion of pseudopodia. The steep PIP3 gradient is also controlled by
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degradation of PIP3 by phosphatases,mainly at the rear side of the
migrating cell. PTEN was found to be a dominant phosphatase for
PIP3 degradation in Dictyostelium (Funamoto et al., 2002; Iijima
et al., 2002, 2004). In contrast, PTEN played only a minor role
in chemotaxis of neutrophils (Subramanian et al., 2007) where
SHIP1 was the major regulator (Nishio et al., 2007). This ﬁnding
was supported by experiments indicating that neutrophils lack-
ing SHIP1 exhibited severe defects in neutrophil polarization and
motility. In macrophages, PTEN was found to control PI3K activ-
ity via negative feedback including the PI3K/Rho/ROCK pathway
(Papakonstanti et al., 2007). These results show that several alter-
native pathways are involved in chemotaxis. One of them could
involve another lipid signaling pathway parallel to PI3K and medi-
ated through phospholipase A2 (PLA2; Chen et al., 2007). Each
of these pathways can inhibit chemotaxis in shallow gradients,
whereas inhibition of chemotaxis in steep gradients requires both
pathways to be disrupted (Kolsch et al., 2008; Wang et al., 2011).
The behavior of cells in different concentration gradients is
diverse. In steep gradients, neutrophils and Dictyostelium can
project pseudopodia directly up the gradient and move toward
the chemoattractant source with only little deviation. In shallower
gradients, cells produce daughter pseudopods and then choose
the one that leads up to the highest concentration of chemoat-
tractant. However, in the weakest gradients the movement of
neutrophils and Dictyostelium looks like a biased random walk
(Kay et al., 2008; Insall, 2010). Key regulators of cellular polar-
ity in migrating neutrophils and Dictyostelium are mTORC2 (Liu
et al., 2010) and TORC2 (Lee et al., 2005). Neutrophils lacking
mTORC2 activity had strongly reduced chemotactic ability, and
were unable to polarize. Actin polymerization and myosin II reg-
ulation were impaired independently. Also production of cAMP
was affected. The effect of mTORC2 on myosin II ﬁlament assem-
bly was mediated via cAMP, RhoA, and ROCK-dependent way
(Charest and Firtel, 2010; Charest et al., 2010; Liu et al., 2010).
Myosin phosphorylation stimulates its activity but the stability
of myosin ﬁlaments is regulated by its dephosphorylation. Based
on these and other studies it was concluded that activation of
the receptors triggers both promoting and inhibiting signals for
myosin phosphorylation and dephosphorylation, and this cycling
is important for optimalmigration (Liu et al., 2010).A recent study
with Dictyostelium mutants focused on better understanding of
the roles of PI3K, TORC2, PLA2, and soluble guanylate cyclase in
chemotaxis in gradients of different strength. The study showed
that Ras activation at the leading edgewas a basal signalingmodule
sufﬁcient for chemotaxis in this system. The enzymes under study
were not required for Ras activation in steep gradients of cAMP
but were important for the direction and improved orientation in
shallow cAMP gradients (Kortholt et al., 2011).
CONCLUDING REMARKS
Mast cells are known for their role in allergy and as effector cells
of innate immunity. They are distributed everywhere in the body
and are enriched at boundaries of the body, such as respiratory
and gastrointestinal mucosa and skin. They are also found near
blood vessels and nerve endings where they contribute to protec-
tion against various pathogens. They must be recruitable to all
these sites by precise cumulation mechanisms to warrant equal
distribution without any crowding or insufﬁcient representation
in some places. This would explain why mast cells have so many
surface receptors involved in chemotaxis. On the other hand, an
important homeostatic role of a crosstalk between mast cells and
other immune and non-immune cells and its enhancement after
mast cell triggering could explain why mast cells produce so many
chemoattractants and why this production is enhanced after mast
cell activation. Furthermore, mast cells of human and mouse ori-
gin also differ in the expression of chemoattractant receptors and
chemoattractants produced (Table 1).
Although numerous molecules have been identiﬁed as signiﬁ-
cant players in chemotaxis, it is very likely that other molecules
involved in chemotaxis will be discovered. Some controversial
results mentioned in this review are attributable to different mast
cell types used, various methods used for detection of chemotaxis
or some additional factors like culture conditions, number of pas-
sages of in vitro cultured cells before the cells are used, origin of
mast cells, age and genotype of donors and others. The crosstalk
between different receptors and signaling molecules is still an
open question, which remains also to be solved. Important data
reﬂecting cellular potential and commitment can be expected from
analysis of whole genome transcriptome of the cells under study
and from application of methods of systems biology in studies of
mast cell chemotaxis under in vitro and in vivo conditions.
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